A Trail of a Novel Tracheal Radioactive Stent for the Malignant Airway Obstruction
Primary Purpose
Malignant Airway Obstruction
Status
Unknown status
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Traditional airway stent
Iodine-125 seeds
Sponsored by
About this trial
This is an interventional treatment trial for Malignant Airway Obstruction focused on measuring Trachea, Stent, Intraluminal brachytherapy
Eligibility Criteria
Inclusion Criteria:
- aged between 18 and 80 years
- MAO caused by any adenocarcinoma with histologically or cytologically confirmation by biopsy or previous surgical procedures
- symptoms such as dyspnea related to biliary obstruction
- unresectability or refusal to be surgically treated
- willing and able to comply with the study procedures and provide written informed consent to participate
Exclusion Criteria:
- patients with suspected benign airway obstruction
- airway obstruction that could not be dilated enough to pass the delivery system
- perforation of any ducts within the tracheal tree
- presence of metallic tracheal stent or airway surgery
- acute or chronic inflammation in the airway
- uncooperative or could not provide authorization and signature.
Sites / Locations
- Zhongda Hospital,Southeast UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Radioactive stent
Traditional airway stent
Arm Description
Patients diagnosed as MAO treated with radioactive airway stent loaded with Iodine-125 seeds
Patients diagnosed as MAO treated with traditional airway stent
Outcomes
Primary Outcome Measures
diameter stenosis
reference tracheal diameter minus minimum diameter at stenosis site / reference tracheal diameter×100
Secondary Outcome Measures
Over survival
Time from stenting to the day when the patients died or lost to the follow-up.
Full Information
NCT ID
NCT02565927
First Posted
September 20, 2015
Last Updated
September 29, 2015
Sponsor
Zhongda Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02565927
Brief Title
A Trail of a Novel Tracheal Radioactive Stent for the Malignant Airway Obstruction
Official Title
A Novel Tracheal Radioactive Stent Loaded With 125I Seeds for the Malignant Airway Obstruction Versus a Conventional Stent: A Prospective Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2015
Overall Recruitment Status
Unknown status
Study Start Date
May 2015 (undefined)
Primary Completion Date
August 2016 (Anticipated)
Study Completion Date
September 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zhongda Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study was to evaluate the safety and effectiveness of an radioactive airway stent loaded with 125I seeds compared to a conventional airway stent in patients with malignant airway obstruction caused by both primary and metastatic malignant tumors.
Detailed Description
Malignant tumors of the lung, esophagus, thyroid, or other mediastinal structures often involve the trachea by direct tumor growth compression and (or) invasion. In addition, extrathoracic cancers metastasize to these lymph nodes as well. However, surgical resection and airway reconstruction are the gold-standard treatment for MAO, many patients with airway involvement are poor surgical candidates based on physiologic or oncologic criteria.There are three main types of malignant airway obstruction: endobronchial obstruction, extrinsic compression, and a mixed pattern. For endobronchial obstruction, ablative techniques that destroy tissue are indicated, including lasers, electrocautery, argon plasma coagulation (APC), photodynamic therapy, microdebriders, and cryotherapy, but primary tracheal cancers are less common than other types of lung cancer. If the obstruction is exclusively or mainly due to compression from outside the airway wall, the only option consists of placement of a stent or endoprosthesis. However, follow-up data has demonstrated that postoperative restenosis of stenting occurs in 5-45% of cases as a result of neoplastic infiltration through the mesh into the lumen or tumor overgrowth above and below the mesh stents. Encouraged by the success of 125I esophageal and biliary stent in esophageal carcinoma , a tracheal stent loaded with 125I radioactive seeds was developed in investigators'institute. After successful in vitro and in vivo evaluations of the delivery system, investigator will prospectively compare responses to treatment with this irradiation tracheal stent versus the conventional self-expandable stent in patients with MAO.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malignant Airway Obstruction
Keywords
Trachea, Stent, Intraluminal brachytherapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Radioactive stent
Arm Type
Experimental
Arm Description
Patients diagnosed as MAO treated with radioactive airway stent loaded with Iodine-125 seeds
Arm Title
Traditional airway stent
Arm Type
Active Comparator
Arm Description
Patients diagnosed as MAO treated with traditional airway stent
Intervention Type
Device
Intervention Name(s)
Traditional airway stent
Other Intervention Name(s)
Tracheal stent(Nanjing MicroInvasive Medical Inc.)
Intervention Description
process airway stenting
Intervention Type
Drug
Intervention Name(s)
Iodine-125 seeds
Other Intervention Name(s)
Radioactive seeds(Chinese Atomic Energy Science Institution)
Intervention Description
process intraluminal brachytherapy
Primary Outcome Measure Information:
Title
diameter stenosis
Description
reference tracheal diameter minus minimum diameter at stenosis site / reference tracheal diameter×100
Time Frame
Participants will be followed till die or lost to follow-up,an expected average of a year.
Secondary Outcome Measure Information:
Title
Over survival
Description
Time from stenting to the day when the patients died or lost to the follow-up.
Time Frame
Participants will be followed till die or lost to follow-up,an expected average of a year.
Other Pre-specified Outcome Measures:
Title
Success rate
Description
The rate of relief of the symptoms and signs of the patients
Time Frame
Participants will be followed till die or lost to follow-up,an expected average of a year.
Title
Number of participants with abnormal laboratory values that are telated to treatment
Description
laboratory examination of white blood cells, IgA, IgG and IgM.
Time Frame
Participants will be followed till die or lost to follow-up,an expected average of a year.
Title
Number of participants with adverse events that are telated to treatment
Description
Adverse events as follows: severe chest pain, hemoptysis, perforation, pneumonia
Time Frame
Participants will be followed till die or lost to follow-up,an expected average of a year.
Title
dyspnea index
Description
Dyspnea index grades are as follows: grade 0,asymptomatic while climbing stairs; grade I, symptomatic climbing stairs; grade II, symptomatic after walking 100 m on flat ground; grade III, symptomatic with the least effort (talking,getting dressed); and grade IV, symptomatic in bed, at rest.
Time Frame
Participants will be followed till die or lost to follow-up,an expected average of a year.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
aged between 18 and 80 years
MAO caused by any adenocarcinoma with histologically or cytologically confirmation by biopsy or previous surgical procedures
symptoms such as dyspnea related to biliary obstruction
unresectability or refusal to be surgically treated
willing and able to comply with the study procedures and provide written informed consent to participate
Exclusion Criteria:
patients with suspected benign airway obstruction
airway obstruction that could not be dilated enough to pass the delivery system
perforation of any ducts within the tracheal tree
presence of metallic tracheal stent or airway surgery
acute or chronic inflammation in the airway
uncooperative or could not provide authorization and signature.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yong Wang, Ph.D
Email
medicalusing@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gao-jun Teng, Ph.D,MD
Organizational Affiliation
Zhongda Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Zhongda Hospital,Southeast University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210009
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yong Wang, Ph.D
12. IPD Sharing Statement
Learn more about this trial
A Trail of a Novel Tracheal Radioactive Stent for the Malignant Airway Obstruction
We'll reach out to this number within 24 hrs